PDF(Pubmed)
Abstract：
The pan-immune-inflammation value (PIV), calculated as (neutrophil × platelet × monocyte)/lymphocyte count, may be useful for estimating survival in breast cancer patients. To determine the prognostic value of PIV for overall survival in breast cancer patients in Lima, Peru. A retrospective cohort study was conducted. 97 breast cancer patients diagnosed between January 2010 and December 2016 had their medical records analyzed. The primary dependent variable was overall survival, and the key independent variable was the PIV, divided into high (≥ 310) and low (< 310) groups. Patient data included demographics, treatment protocols and other clinical variables. Statistical analysis involved Kaplan-Meier survival curves and Cox proportional hazards modeling. Patients with a PIV ≥ 310 had significantly lower 5-year survival functions (p = 0.004). Similar significant differences in survival were observed for clinical stage III-IV (p = 0.015), hemoglobin levels < 12 mg/Dl (p = 0.007), histological grade (p = 0.019), and nuclear grade (p < 0.001); however, molecular classification did not show a significant survival difference (p = 0.371). The adjusted Hazard Ratios showed that PIV ≥ 310 was significantly associated with poor outcome (5.08, IC95%: 1.52-16.92). While clinical stage and hemoglobin levels were associated with survival in the unadjusted model. These factors did not maintain significance after adjustment. PIV is an independent predictor of reduced survival in Peruvian breast cancer patients.
摘要：
泛免疫炎症值(PIV)，计算为（中性粒细胞×血小板×单核细胞）/淋巴细胞计数，可能有助于估计乳腺癌患者的生存率。为了确定PIV对利马乳腺癌患者总生存期的预后价值，秘鲁。进行了一项回顾性队列研究。分析了2010年1月至2016年12月间确诊的97例乳腺癌患者的医疗记录。主要因变量是总生存率，关键的自变量是PIV，分为高（≥310）和低（<310）组。患者数据包括人口统计学，治疗方案和其他临床变量。统计分析包括Kaplan-Meier存活曲线和Cox比例风险模型。PIV≥310的患者的5年生存功能显着降低（p=0.004）。在临床III-IV期（p=0.015）中观察到类似的显着差异，血红蛋白水平<12mg/Dl（p=0.007），组织学分级（p=0.019），和核等级(p<0.001)；然而，分子分类没有显示显著的生存差异(p=0.371)。调整后的危险比显示，PIV≥310与不良结局显着相关（5.08，IC95%：1.52-16.92）。而在未调整的模型中，临床分期和血红蛋白水平与生存率相关。这些因素在调整后没有保持显著性。PIV是秘鲁乳腺癌患者生存率降低的独立预测因子。
